Industry Research Reports

Home > Reports > Medical Devices & Consumables > Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Devices & Consumables

Published Date: 2024-01-11

Pages: 109 Pages

Report ld: 3028877

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Radioligand Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for Radioligand Therapy was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Radioligand Therapy was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Radioligand Therapy was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG and Curium Pharma, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

MARKET SEGMENTATION

By Company

Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides

Segment by Application

Neuroendocrine Neoplasms
Prostate Cancer

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Radioligand Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radioligand Therapy by region & country, by Type, and by Application.

The Radioligand Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioligand Therapy.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Radioligand Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Radioligand Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Radioligand Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Radioligand Therapy Product Introduction

1.2 Global Radioligand Therapy Market Size Forecast

1.3 Radioligand Therapy Market Trends & Drivers

1.3.1 Radioligand Therapy Industry Trends

1.3.2 Radioligand Therapy Market Drivers & Opportunity

1.3.3 Radioligand Therapy Market Challenges

1.3.4 Radioligand Therapy Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Radioligand Therapy Players Revenue Ranking (2023)

2.2 Global Radioligand Therapy Revenue by Company (2019-2024)

2.3 Key Companies Radioligand Therapy Manufacturing Base Distribution and Headquarters

2.4 Key Companies Radioligand Therapy Product Offered

2.5 Key Companies Time to Begin Mass Production of Radioligand Therapy

2.6 Radioligand Therapy Market Competitive Analysis

2.6.1 Radioligand Therapy Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Radioligand Therapy Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Actinium 225 (Ac-225)

3.1.2 Lutetium 177 (Lu-177)

3.1.3 Gallium 68 (Ga-68)

3.1.4 Fluorine 18 (F-18)

3.1.5 Other Radionuclides

3.2 Global Radioligand Therapy Sales Value by Type

3.2.1 Global Radioligand Therapy Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Radioligand Therapy Sales Value, by Type (2019-2030)

3.2.3 Global Radioligand Therapy Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Neuroendocrine Neoplasms

4.1.2 Prostate Cancer

4.2 Global Radioligand Therapy Sales Value by Application

4.2.1 Global Radioligand Therapy Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Radioligand Therapy Sales Value, by Application (2019-2030)

4.2.3 Global Radioligand Therapy Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Radioligand Therapy Sales Value by Region

5.1.1 Global Radioligand Therapy Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Radioligand Therapy Sales Value by Region (2019-2024)

5.1.3 Global Radioligand Therapy Sales Value by Region (2025-2030)

5.1.4 Global Radioligand Therapy Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Radioligand Therapy Sales Value, 2019-2030

5.2.2 North America Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Radioligand Therapy Sales Value, 2019-2030

5.3.2 Europe Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Radioligand Therapy Sales Value, 2019-2030

5.4.2 Asia Pacific Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Radioligand Therapy Sales Value, 2019-2030

5.5.2 South America Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Radioligand Therapy Sales Value, 2019-2030

5.6.2 Middle East & Africa Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Radioligand Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Radioligand Therapy Sales Value

6.3 United States

6.3.1 United States Radioligand Therapy Sales Value, 2019-2030

6.3.2 United States Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Radioligand Therapy Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Radioligand Therapy Sales Value, 2019-2030

6.4.2 Europe Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Radioligand Therapy Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Radioligand Therapy Sales Value, 2019-2030

6.5.2 China Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.5.3 China Radioligand Therapy Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Radioligand Therapy Sales Value, 2019-2030

6.6.2 Japan Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Radioligand Therapy Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Radioligand Therapy Sales Value, 2019-2030

6.7.2 South Korea Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Radioligand Therapy Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Radioligand Therapy Sales Value, 2019-2030

6.8.2 Southeast Asia Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Radioligand Therapy Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Radioligand Therapy Sales Value, 2019-2030

6.9.2 India Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

6.9.3 India Radioligand Therapy Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Novartis

7.1.1 Novartis Profile

7.1.2 Novartis Main Business

7.1.3 Novartis Radioligand Therapy Products, Services and Solutions

7.1.4 Novartis Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.1.5 Novartis Recent Developments

7.2 Advanced Accelerator Applications

7.2.1 Advanced Accelerator Applications Profile

7.2.2 Advanced Accelerator Applications Main Business

7.2.3 Advanced Accelerator Applications Radioligand Therapy Products, Services and Solutions

7.2.4 Advanced Accelerator Applications Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.2.5 Advanced Accelerator Applications Recent Developments

7.3 Mercy Radiology

7.3.1 Mercy Radiology Profile

7.3.2 Mercy Radiology Main Business

7.3.3 Mercy Radiology Radioligand Therapy Products, Services and Solutions

7.3.4 Mercy Radiology Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.3.5 POINT Biopharma Global Inc Recent Developments

7.4 POINT Biopharma Global Inc

7.4.1 POINT Biopharma Global Inc Profile

7.4.2 POINT Biopharma Global Inc Main Business

7.4.3 POINT Biopharma Global Inc Radioligand Therapy Products, Services and Solutions

7.4.4 POINT Biopharma Global Inc Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.4.5 POINT Biopharma Global Inc Recent Developments

7.5 Fusion Pharma

7.5.1 Fusion Pharma Profile

7.5.2 Fusion Pharma Main Business

7.5.3 Fusion Pharma Radioligand Therapy Products, Services and Solutions

7.5.4 Fusion Pharma Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.5.5 Fusion Pharma Recent Developments

7.6 Telix Pharmaceuticals Ltd

7.6.1 Telix Pharmaceuticals Ltd Profile

7.6.2 Telix Pharmaceuticals Ltd Main Business

7.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Products, Services and Solutions

7.6.4 Telix Pharmaceuticals Ltd Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.6.5 Telix Pharmaceuticals Ltd Recent Developments

7.7 Lantheus Holdings, Inc

7.7.1 Lantheus Holdings, Inc Profile

7.7.2 Lantheus Holdings, Inc Main Business

7.7.3 Lantheus Holdings, Inc Radioligand Therapy Products, Services and Solutions

7.7.4 Lantheus Holdings, Inc Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.7.5 Lantheus Holdings, Inc Recent Developments

7.8 Bayer AG

7.8.1 Bayer AG Profile

7.8.2 Bayer AG Main Business

7.8.3 Bayer AG Radioligand Therapy Products, Services and Solutions

7.8.4 Bayer AG Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.8.5 Bayer AG Recent Developments

7.9 Curium Pharma

7.9.1 Curium Pharma Profile

7.9.2 Curium Pharma Main Business

7.9.3 Curium Pharma Radioligand Therapy Products, Services and Solutions

7.9.4 Curium Pharma Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.9.5 Curium Pharma Recent Developments

7.10 Precirix

7.10.1 Precirix Profile

7.10.2 Precirix Main Business

7.10.3 Precirix Radioligand Therapy Products, Services and Solutions

7.10.4 Precirix Radioligand Therapy Revenue (US$ Million) & (2019-2024)

7.10.5 Precirix Recent Developments

8 Industry Chain Analysis

8.1 Radioligand Therapy Industrial Chain

8.2 Radioligand Therapy Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Radioligand Therapy Sales Model

8.5.2 Sales Channel

8.5.3 Radioligand Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Radioligand Therapy Market Trends

Table 2. Radioligand Therapy Market Drivers & Opportunity

Table 3. Radioligand Therapy Market Challenges

Table 4. Radioligand Therapy Market Restraints

Table 5. Global Radioligand Therapy Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Radioligand Therapy Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Radioligand Therapy Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Radioligand Therapy Product Type

Table 9. Key Companies Time to Begin Mass Production of Radioligand Therapy

Table 10. Global Radioligand Therapy Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Radioligand Therapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Radioligand Therapy Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Radioligand Therapy Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Radioligand Therapy Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Radioligand Therapy Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Radioligand Therapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Radioligand Therapy Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Radioligand Therapy Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Radioligand Therapy Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Radioligand Therapy Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Radioligand Therapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Radioligand Therapy Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Radioligand Therapy Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Radioligand Therapy Sales Value by Region (2019-2024) & (%)

Table 27. Global Radioligand Therapy Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Radioligand Therapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Radioligand Therapy Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Radioligand Therapy Sales Value, (2025-2030) & (US$ Million)

Table 31. Novartis Basic Information List

Table 32. Novartis Description and Business Overview

Table 33. Novartis Radioligand Therapy Products, Services and Solutions

Table 34. Revenue (US$ Million) in Radioligand Therapy Business of Novartis (2019-2024)

Table 35. Novartis Recent Developments

Table 36. Advanced Accelerator Applications Basic Information List

Table 37. Advanced Accelerator Applications Description and Business Overview

Table 38. Advanced Accelerator Applications Radioligand Therapy Products, Services and Solutions

Table 39. Revenue (US$ Million) in Radioligand Therapy Business of Advanced Accelerator Applications (2019-2024)

Table 40. Advanced Accelerator Applications Recent Developments

Table 41. Mercy Radiology Basic Information List

Table 42. Mercy Radiology Description and Business Overview

Table 43. Mercy Radiology Radioligand Therapy Products, Services and Solutions

Table 44. Revenue (US$ Million) in Radioligand Therapy Business of Mercy Radiology (2019-2024)

Table 45. Mercy Radiology Recent Developments

Table 46. POINT Biopharma Global Inc Basic Information List

Table 47. POINT Biopharma Global Inc Description and Business Overview

Table 48. POINT Biopharma Global Inc Radioligand Therapy Products, Services and Solutions

Table 49. Revenue (US$ Million) in Radioligand Therapy Business of POINT Biopharma Global Inc (2019-2024)

Table 50. POINT Biopharma Global Inc Recent Developments

Table 51. Fusion Pharma Basic Information List

Table 52. Fusion Pharma Description and Business Overview

Table 53. Fusion Pharma Radioligand Therapy Products, Services and Solutions

Table 54. Revenue (US$ Million) in Radioligand Therapy Business of Fusion Pharma (2019-2024)

Table 55. Fusion Pharma Recent Developments

Table 56. Telix Pharmaceuticals Ltd Basic Information List

Table 57. Telix Pharmaceuticals Ltd Description and Business Overview

Table 58. Telix Pharmaceuticals Ltd Radioligand Therapy Products, Services and Solutions

Table 59. Revenue (US$ Million) in Radioligand Therapy Business of Telix Pharmaceuticals Ltd (2019-2024)

Table 60. Telix Pharmaceuticals Ltd Recent Developments

Table 61. Lantheus Holdings, Inc Basic Information List

Table 62. Lantheus Holdings, Inc Description and Business Overview

Table 63. Lantheus Holdings, Inc Radioligand Therapy Products, Services and Solutions

Table 64. Revenue (US$ Million) in Radioligand Therapy Business of Lantheus Holdings, Inc (2019-2024)

Table 65. Lantheus Holdings, Inc Recent Developments

Table 66. Bayer AG Basic Information List

Table 67. Bayer AG Description and Business Overview

Table 68. Bayer AG Radioligand Therapy Products, Services and Solutions

Table 69. Revenue (US$ Million) in Radioligand Therapy Business of Bayer AG (2019-2024)

Table 70. Bayer AG Recent Developments

Table 71. Curium Pharma Basic Information List

Table 72. Curium Pharma Description and Business Overview

Table 73. Curium Pharma Radioligand Therapy Products, Services and Solutions

Table 74. Revenue (US$ Million) in Radioligand Therapy Business of Curium Pharma (2019-2024)

Table 75. Curium Pharma Recent Developments

Table 76. Precirix Basic Information List

Table 77. Precirix Description and Business Overview

Table 78. Precirix Radioligand Therapy Products, Services and Solutions

Table 79. Revenue (US$ Million) in Radioligand Therapy Business of Precirix (2019-2024)

Table 80. Precirix Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Radioligand Therapy Downstream Customers

Table 84. Radioligand Therapy Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Radioligand Therapy Product Picture

Figure 2. Global Radioligand Therapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Radioligand Therapy Sales Value (2019-2030) & (US$ Million)

Figure 4. Radioligand Therapy Report Years Considered

Figure 5. Global Radioligand Therapy Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Radioligand Therapy Revenue in 2023

Figure 7. Radioligand Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Actinium 225 (Ac-225) Picture

Figure 9. Lutetium 177 (Lu-177) Picture

Figure 10. Gallium 68 (Ga-68) Picture

Figure 11. Fluorine 18 (F-18) Picture

Figure 12. Other Radionuclides Picture

Figure 13. Global Radioligand Therapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Radioligand Therapy Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Neuroendocrine Neoplasms

Figure 16. Product Picture of Prostate Cancer

Figure 17. Global Radioligand Therapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Radioligand Therapy Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Radioligand Therapy Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Radioligand Therapy Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Radioligand Therapy Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Radioligand Therapy Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Radioligand Therapy Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Radioligand Therapy Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Radioligand Therapy Sales Value (%), (2019-2030)

Figure 30. United States Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 36. China Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 38. China Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 48. India Radioligand Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Radioligand Therapy Sales Value by Type (%), 2023 VS 2030

Figure 50. India Radioligand Therapy Sales Value by Application (%), 2023 VS 2030

Figure 51. Radioligand Therapy Industrial Chain

Figure 52. Radioligand Therapy Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Radioligand Therapy market? zhanKai

The top companies in the global Radioligand Therapy market are Novartis、Advanced Accelerator Applications、Mercy Radiology.

Related Reports

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Radioligand Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-06-16
Pages: 110
USD 3950.00
(Single User License)
Global Radioligand Therapy Market Research Report 2026
The global Radioligand Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-17
Pages: 103
USD 2900.00
(Single User License)
Global Radioligand Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Radioligand Therapy market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-11-02
Pages: 80
USD 4250.00
(Single User License)
Global Radioligand Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Radioligand Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-02
Pages: 128
USD 4900.00
(Single User License)
Radioligand Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Radioligand Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 91
USD 3950.00
(Single User License)
Global Radioligand Therapy Market Research Report 2025
The global market for Radioligand Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-01
Pages: 79
USD 2900.00
(Single User License)
Global Radioligand Therapy Market Research Report 2024
The global Radioligand Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-02-06
Pages: 82
USD 2900.00
(Single User License)

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Radioligand Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-06-16
Pages: 110
USD 3950.00 (Single User License)
Global Radioligand Therapy Market Research Report 2026
The global Radioligand Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-17
Pages: 103
USD 2900.00 (Single User License)
Global Radioligand Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Radioligand Therapy market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-11-02
Pages: 80
USD 4250.00 (Single User License)
Global Radioligand Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Radioligand Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-02
Pages: 128
USD 4900.00 (Single User License)
Radioligand Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Radioligand Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 91
USD 3950.00 (Single User License)
Global Radioligand Therapy Market Research Report 2025
The global market for Radioligand Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-01
Pages: 79
USD 2900.00 (Single User License)
Global Radioligand Therapy Market Research Report 2024
The global Radioligand Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-02-06
Pages: 82
USD 2900.00 (Single User License)